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The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for
degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently
unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties.
In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2
protein of influenza A virus. We constructed chimeric vpu gene in which the transmembrane domain of Vpu was replaced with that of the M2
protein of influenza. This chimeric vpu gene was substituted for the vpu gene in the genome of a pathogenic simian human immunodeficiency
virus, SHIVKU-1bMC33. The resulting virus, SHIVM2, synthesized a Vpu protein that had a slightly different Mr compared to the parental
SHIVKU-1bMC33, reflecting the different sizes of the two Vpu proteins. The SHIVM2 was shown to replicate with slightly reduced kinetics when
compared to the parental SHIVKU-1bMC33 but electron microscopy revealed that the site of maturation was similar to the parental virus
SHIVKU1bMC33. We show that the replication and spread of SHIVM2 could be blocked with the antiviral drug rimantadine, which is known to
target the M2 ion channel. Our results indicate a dose dependent inhibition of SHIVM2 with 100 AM rimantadine resulting in a >95% decrease in
p27 released into the culture medium. Rimantadine did not affect the replication of the parental SHIVKU-1bMC33. Examination of SHIVM2-infected
cells treated with 50 AM rimantadine revealed numerous viral particles associated with the cell plasma membrane and within intracytoplasmic
vesicles, which is similar to HIV-1 mutants lacking a functional vpu. To determine if SHIVM2 was as pathogenic as the parental SHIVKU-1bMC33
virus, two pig-tailed macaques were inoculated and followed for up to 8 months. Both pig-tailed macaques developed severe CD4+ T cell loss
within 1 month of inoculation, high viral loads, and histological lesions consistent with lymphoid depletion similar to the parental SHIVKU-1bMC33.
Taken together, these results indicate for the first time that the TM domain of the Vpu protein can be functionally substituted with the TM of M2 of
influenza A virus, and shows that compounds that target the TM domain of Vpu protein of HIV-1 could serve as novel anti-HIV-1 drugs.
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Human immunodeficiency virus type 1 (HIV-1) and several
strains of simian immunodeficiency viruses (SIV) isolated from6) 541 – 559
www.e
Fig. 1. Sequence of the proteins analyzed in this study. The () introduced in the VpuM2 sequence was for purposes of sequence alignment.
D.R. Hout et al. / Virology 344 (2006) 541–559542non-human primates encode for a small membrane bound
protein known as the Vpu protein (Strebel et al., 1988; Cohen
et al., 1988; Huet et al., 1990; Barlow et al., 2003; Courgnaud
et al., 2002; 2003). The Vpu protein from laboratory-adapted
subtype B HIV-1 has been extensively studied with respect to
its role in the virus life cycle and has resulted in the
identification of two major functions in replication. The Vpu
down-regulates the CD4 receptor in the rough endoplasmic
reticulum (RER) and shunts it to the proteasome for
degradation (Fujita et al., 1997; Schubert et al., 1998). Studies
have shown that the highly conserved hinge region containing
two casein kinase II sites is required for the CD4 degradation
(Schubert et al., 1994; Paul and Jabbar, 1997) and other studies
have shown that the predicted two a-helical domains within the
cytoplasmic domain and sequences within the transmembrane
(TM) domain are also required for efficient degradation of CD4Fig. 2. VpuM2EGFP is expressed in the same intracellular compartments as the wild
VpuM2EGFP and DsRed2-ER or ECFP-Golgi. At 48 h, cells expressing EGFP an
confocal microscopy as described in the Materials and methods section. (A–D)
VpuEGFP. (B) Expression of ECFP-Golgi. (C) Merge of panels A and B. (D) Fluores
H) 293 cells co-transfected with VpuM2EGFP and ECFP-Golgi. (E) Expression of V
Fluorescence micrograph of EGFP and ECFP fusion proteins from panels E and F. (I–
VpuM2EGFP. (J) Expression of DsRed2-ER. (K) Merge of panels I and J. (L) Fluor(Tiganos et al., 1998). Additionally, Vpu also enhances virus
release from infected cells (Klimkait et al., 1990). Examination
of cells infected with HIV-1 viruses containing large deletions
within the vpu gene by electron microscopy revealed a
different pattern of virus maturation with many particles
tethered together at the cell surface and within intracellular
vesicles. Some investigators have mapped Vpu-mediated virion
release to the TM domain and other investigators have
provided evidence that the TM domain forms an ion channel
(Ewart et al., 1996; Schubert et al., 1996a). This evidence
suggests that Vpu of HIV-1 is a member of a class of viral
proteins known as the viroporins, which include the M2 protein
of influenza A virus, the 6K protein of Sindbis virus (SV), and
the 2B protein of poliovirus (Gonzalez and Carrasco, 2003).
In a previous study, evidence was provided that one viroporin
could substitute for one another (Gonzalez and Carrasco, 2001).type Vpu. 293 cells were co-transfected with vectors expressing VpuEGFP or
d DsRed2 or ECFP were identified and images collected using laser scanning
293 cells co-transfected with VpuEGFP and ECFP-Golgi. (A) Expression of
cence micrograph of EGFP and ECFP fusion proteins from panels A and B. (E–
puM2EGFP. (F) Expression of ECFP-Golgi. (G) Merge of panels E and F. (H)
L) 293 cells co-transfected with VpuM2EGFP and DsRed2-ER. (I) Expression of
escence micrograph of EGFP and DsRed2 fusion proteins from panels I and J.
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could substitute for the 6K protein of SV, which facilitates
budding of virus particles and regulates transport of viral
glycoproteins through the secretory pathway. Transfection of
BHK cells with an SV vector that did not express the 6K protein,
pSVDelta6K, resulted in lower membrane permeabilization,
impaired glycoprotein processing, and deficient virion budding.
These investigators showed that expression of Vpu protein
under a duplicated late promoter (pSVDelta6KVpu) restored
enhanced membrane permeability, normal glycoprotein precur-
sor processing, and facilitated infectious virus particle produc-
tion. Other studies have shown that derivatives of the Na+ K+
antiporter amlioride could inhibit the Vpu ion channel and
decrease virus release from cells (Ewart et al., 2002, 2004).
Our laboratory has been using the chimeric simian human
immunodeficiency/macaque model to study the role of Vpu
and its various domains in CD4+ T cell loss and pathogenesis
(Stephens et al., 2002; Singh et al., 2003; Hout et al., 2004a,
2005). Using a pathogenic molecular clone known as
SHIVKU-1bMC33, we showed that the Vpu does indeed
contribute to pathogenesis (Stephens et al., 2002). More
recently, we have shown that the casein kinase II sites within
the cytoplasmic domain and the TM domain of Vpu contribute
to the pathogenicity of this virus (Singh et al., 2003; Hout et
al., 2005). In this study, we constructed a simian–humanFig. 3. CD4 down-regulation by EGFP, VpuEGFP, and VpuM2EGFP. HeLa CD4
VpuEGFP, or VpuM2EGFP. At 48 h post-transfection, cells were stained for surface
followed by fixation with 1% formalin. Cells were examined by laser scanning conf
expression and layered onto a phase contrast image of the cell. (B, F, and J) Cells w
onto a phase contrast image of the cells. (C, G, and K) Fluorescent micrographs mer
EGFP. (E–H) Cells transfected with a vector expressing VpuEGFP. (I –L) Cells traimmunodeficiency virus (SHIVM2) mutant in which the
transmembrane domain of Vpu was changed to the TM
domain of the prototypical viroporin, the M2 protein of
influenza A virus. Our results show that this chimeric Vpu was
capable of down-regulating CD4 from the cell surface, that the
replication of a virus was constructed with this chimeric
protein (SHIVM2) was sensitive to the effects of rimantadine,
and that inoculation of pig-tailed macaques with the SHIVM2
virus resulted in severe CD4+ T cell loss and AIDS. These
results show for the first time that the ion channel from the M2
protein (i.e., the TM domain of the M2 protein) and Vpu can
be exchanged and suggests a ‘‘commonality’’ with respect to
their involvement in virus maturation from cells. Finally, these
results provide ‘‘proof of concept’’ that compounds that
interact with and perturb the function of the TM domain of
Vpu could represent a novel class of anti-HIV-1 drugs (Fig. 1).
Results
Expression of the VpuM2EGFP reveals a similar intracellular
localization to the unmodified protein and is functional for
CD4 down-modulation
We analyzed the intracellular transport of the VpuM2
protein by fusion to the enhanced green fluorescent protein+ cells, which express CD4, were transfected with vectors expressing EGFP,
CD4 using a-CD4 antibody and a rhodamine conjugated secondary antibody
ocal microscopy. (A, E, and I) Cells examined using a filter to visualize EGFP
ere examined using a filter to identify cell surface CD4 expression and layered
ging EGFP and CD4 images. (A–D) Cells transfected with a vector expressing
nsfected with a vector expressing VpuM2EGFP.
Fig. 4. Immunoprecipitation of Vpu proteins from SHIVKU-1bMC33- and
SHIVM2-inoculated cultures and p27 growth curves. (A) C8166 cultures were
inoculated with SHIVKU-1bMC33 or SHIVM2 at an MOI of approximately 0.01
Cultures were incubated for 6 days and then radiolabeled with 35S-methionine
cysteine for 5 h. Vpu proteins were immunoprecipitated from cell lysates using
an a-Vpu serum as described in the Materials and methods section. All samples
were analyzed under reducing conditions by SDS-PAGE (12.5% gel) and
visualized by standard autoradiographic techniques. Lane 1: Vpu proteins
immunoprecipitated from uninoculated cultures. Lane 2: Vpu proteins
immunoprecipitated from SHIVM2-inoculated cultures. Lane 3: Vpu proteins
immunoprecipitated from SHIVKU-1bMC33-inoculated cultures. The location o
the molecular weight markers is shown on the left. (B) Growth curves o
SHIVKU-1bMC33 (.) and SHIVM2 (n) in C8166 cells. Cultures of C8166 cells
were inoculated with either SHIVKU-1bMC33 or SHIVM2 as described in the text
Aliquots of the culture medium were assayed for the presence of p27 antigen
The growth curves were performed in duplicate with the mean value shown.
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transfection with the vectors expressing the unmodified
subtype B protein (VpuEGFP) and ECFP-Golgi resulted in
nearly complete co-localization (Figs. 2A–D). Co-transfection
of 293 cells with the vectors expressing the unmodified
subtype B Vpu protein (VpuEGFP) and DsRed2-ER resulted
in this protein being partially co-localized with this intra-
cellular markers (data shown; Gomez et al., 2005; Pacyniak et
al., 2005). Co-transfection of 293 cells with vectors expressing
VpuM2EGFP and DsRed2-ER resulted in partial localization of
the VpuM2EGFP with the DsRed2-ER (Figs. 2E–H) and is
similar to what we have previously shown for the unmodified
VpuEGFP protein (Gomez et al., 2005; Pacyniak et al., 2005).
Co-transfection of 293 cells with the vectors expressing
VpuM2EGFP and ECFP-Golgi resulted in the two proteins
being almost completely co-localized (Figs. 2I–L). Finally, we
co-transfected cells with the vectors expressing VpuM2EGFP
and ECFP-Mem. Similar to the unmodified VpuEGFP protein,
the VpuM2EGFP did not appear to be expressed on the cell
surface (data not shown). These results indicate that replace-
ment of the Vpu TM domain with that of the M2 protein of
influenza A virus still resulted in a protein that was transported
to the same intracellular compartments as the unmodified Vpu
protein and correlated well with our recent study that identified
the cytoplasmic domain as having a Golgi retention signal
(Pacyniak et al., 2005).
We determined if the VpuM2EGFP was capable of
preventing cell surface expression of CD4. HeLa CD4+ cells
were transfected with vectors expressing EGFP, VpuEGFP,
and VpuM2EGFP. At 48 h post-transfection, live cells were
stained for cell surface CD4, fixed, and examined by
confocal microscopy. As shown in Figs. 3A–D, cells
expressing EGFP did not prevent cell surface CD4 expression
while transfection of HeLa CD4+ cells with a vector
expressing VpuEGFP prevented cell surface expression (Figs.
3E–H), which is similar to what we previously reported
(Pacyniak et al., 2005; Singh et al., 2003). Transfection of
HeLa CD4+ cells with the vector expressing VpuM2EGFP
prevented cell surface expression of CD4 (Figs. 3I–L) and was
similar to the unmodified VpuEGFP. In addition, we performed
co-transfection experiments with vectors expressing EGFP,
VpuEGFP, or VpuM2EGFP and human CD4. The results
confirmed that the VpuEGFP and VpuM2EGFP induced CD4
degradation while CD4 was stably expressed in the presence of
EGFP (data not shown). These results indicate that replacement
of the Vpu TM domain with the TM from the M2 protein did
not affect the ability of Vpu to induce degradation of CD4.
The SHIVM2 virus encodes for a protein that has a slightly
different Mr than the unmodified Vpu protein
We analyzed the expression of the Vpu protein in C8166
cultures inoculated with parental SHIVKU-1bMC33 or SHIVM2.
SHIVKU-1bMC33 expresses the unmodified, full length Vpu as
well as the Tat, Rev, and Env proteins. The SHIVM2 is the
same as the SHIVKU-1bMC33 virus except that the vpu gene
was replaced with the chimeric vpuM2 gene, which expressesa protein in which the transmembrane domain of Vpu has
been replaced with the M2 protein of influenza A virus.
Cultures were inoculated with equivalent amounts of virus and
at 7 days post-inoculation, cells were radiolabeled and Vpu
proteins immunoprecipitated from cell lysates. As shown in
Fig. 4A, a protein with an Mr of 16,000 was immunopreci-
pitated from SHIVKU-1bMC33-inoculated cultures. A Vpu
protein was also immunoprecipitated from SHIVM2-inoculated
C8166 cultures with a slightly slower mobility in SDS-PAGE,
which is probably a reflection of the structure of the VpuM2
protein.
The SHIVM2 virus replicates with kinetics that are slightly
delayed compared to the parental SHIVKU-1bMC33
We performed p27 growth curves to quantify the amount
of virus released following inoculation of C8166 cells..
/
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infectious units of SHIVKU-1bMC33, SHIVTM, or SHIVM2
as determined by titration in the HOS-CXCR4 cell line.
Culture fluids were collected at 0, 1, 3, 5, 7, and 10 days
post-inoculation and assayed for p27 released into the
culture medium. As shown in Fig. 4B, growth curves
revealed slightly reduced kinetics of viral p27 released into
the culture medium when compared to the parental
SHIVKU-1bMC33. We also compared the synthesis and proces-
sing of the SHIVKU-1bMC33 or SHIVM2 viral proteins by
pulse-chase analyses. Our results indicated that the SHIVM2
viral proteins were processed similarly to those of the parental
SHIVKU-1bMC33 virus (data not shown).
The SHIVM2 virus has a maturation pattern that is similar to
the parental SHIVKU-1bMC33 in C8166 cells
Since the p27 assays indicated that the SHIVM2-inoculated
cultures released less virus into the culture medium with
time, we examined cultures inoculated with SHIVM2 and
parental SHIVKU-1bMC33 at 7 days post-inoculation by elec-Fig. 5. Electron microscopy examination of C8166 cells inoculated with SHIVKU-1
inoculated with either SHIVM2 or SHIVKU-1bMC33 for 7 days. Cells were washed th
Materials and methods section. (A) Untreated C8166 cells inoculated with parental S
with 50 AM rimantadine. (C) Untreated C8166 cells inoculated with SHIVM2. (D
rimantadine. (E) C8166 cells inoculated with parental SHIVM2 in the presence of
presence of 50 AM rimantadine.tron microscopy to determine if the pattern of maturation
was different among the two viruses. As shown in Fig. 5A,
SHIVKU-1bMC33-inoculated C8166 cells revealed viral par-
ticles maturing at the cell plasma membrane. The mean
number of virus particles associated with 100 infected cells
was 47.8 (Fig. 6A). Examination of SHIVM2-inoculated
cultures by electron microscopy also revealed virus matur-
ing at the cell plasma membrane (Fig. 5C) with a mean
number of 40 viral particles associated per cell (Fig. 6B),
which was not statistically different from the parental virus.
We did not observe SHIVM2 maturing into intracellular
vesicles as we previously described for other SHIVs with
Vpu mutants, SHIVTM, or SHIVVpenv (Hout et al., 2004b,
2005).
The SHIVM2 virus is sensitive to an inhibitor that blocks the M2
ion channel
As the above results of the pulse-chase analyses and
electron microscopy suggested that the kinetics of viral release
from cells were slightly reduced for SHIVM2 when comparedbMC33 or SHIVM2 in the absence or presence of rimantadine. C8166 cells were
ree times with PBS and processed for electron microscopy as described in the
HIVKU-1bMC33. (B) C8166 cells inoculated with parental SHIVKU-1bMC33 treated
) C8166 cells inoculated with parental SHIVM2 in the presence of 50 AM
50 AM rimantadine. (F) C8166 cells inoculated with parental SHIVM2 in the
Fig. 6. Enumeration of viral particles associated with the infected C8166 cells following inoculation with SHIVKU-1bMC33 (A, C) or SHIVM2 (B, D) in the absence
(A, B) or presence of 50 AM rimantadine. Cells were inoculated with equivalent doses of infectious virus and at 7 days processed for electron microscopy as
described in the Material and methods section. The number of viral particles associated with 100 cells per virus/treatment was enumerated. (A) The distribution of
the number of viral particles per cell following inoculation with SHIVKU-1bMC33. (B) The distribution of the number of viral particles per cell following inoculation
with SHIVM2. (C) The distribution of the number of viral particles per cell following inoculation with SHIVKU-1bMC33 and treatment with 50 AM rimantadine. (D)
The distribution of the number of viral particles per cell following inoculation with SHIVM2 and treatment with 50 AM rimantadine. The mean number of particles
per cell for each virus/treatment is shown at the top of each panel.
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sensitive to inhibitors (amantadine and rimantadine), which are
known to interact with and block the ion channel of the M2
protein (Hay et al., 1986). We first assessed the toxicity of the
amantadine and rimantadine in C8166 cells. Cells were
incubated with 100 AM, 10 AM, 1 AM, or with no rimantadine
or amantadine and the number of viable cells assessed by the
trypan blue dye exclusion method at 0, 1, 3, and 7 days.
Amantadine was found to be somewhat toxic at 100 AM while
rimantadine was not toxic at a concentration of 100 AM (data
not shown). Due to this apparent toxicity associated with 100
AM amantadine, we chose to work with rimantadine. C8166
cells were inoculated with either the parental SHIVKU-1bMC33
virus or SHIVM2 for 4 h, the inoculum removed, and thenincubated for 7 days in medium containing various concentra-
tions of rimantadine (100 AM, 75 AM, 50 AM, 25 AM, or
untreated). At 7 days, the culture supernatants were collected
and assayed for p27 levels. As shown in Fig. 7A, rimantadine
reduced virus release by an average of >99% at 100 AM, 90%
at 75 AM, 63% at 50 AM, and 14% at a 25 AM. At 10 AM,
rimantadine had no effect on p27 release (data not shown).
Rimantadine had no effect on the replication of SHIVKU-1bMC33
in C8166 cultures at any of the tested concentrations (Fig. 7A).
We confirmed the p27 results by radiolabeling infected cells at
7 days post-inoculation with 35S-methionine/cysteine for 12 h.
The culture supernatants were recovered and cell lysates
prepared after the 12 h pulse-labeling and used for immuno-
precipitations using an anti-SHIV serum. As shown in Fig. 7B,
Fig. 7. Rimantadine, an inhibitor of the M2 ion channel, inhibits the replication of SHIVM2 but not parental SHIVKU-1bMC33. (A) C8166 cells were inoculated with
either SHIVM2 or SHIVKU-1bMC33 in the presence of various concentrations of rimantadine or in the absence of rimantadine. At 7 days post-inoculation, culture
supernatants were removed, clarified, and assayed for the presence of p27 antigen. (B, C) At 7 days post-inoculation, untreated or treated cells were starved for
methionine and cysteine and radiolabeled overnight with 35S-methionine/cysteine for 12 h. Viral proteins were immunoprecipitated from the culture medium as
described in the Materials and Methods section from SHIVKU-1bMC33 (B) or SHIVM2 (C). (D) C8166 cells were treated with 50 AM rimantadine for 1 h prior to and
during the initial 4 h inoculation period. The inoculum and rimantadine were removed, cells washed three times, and cultures refed with fresh medium lacking
rimantadine. At 7 days post-inoculation, culture medium was collected and assayed for p27 antigen using antigen capture assays. The p27 assay experiments were
repeated three times and the immunoprecipitations two times.
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of the parental SHIVKU-1bMC33 viral proteins into the culture
medium. In contrast, the levels of SHIVM2 viral proteins
released into the culture medium were reduced in a dose
dependent manner from SHIVM2-inoculated cultures in the
presence of 50 AM to 100 AM rimantadine (Fig. 7C). Thus, the
immunoprecipitation results correlated with the p27 assays.
Taken together, our results indicate that substitution of the Vpu
transmembrane domain with that of the M2 protein from
influenza A virus resulted in a SHIV that was sensitive to the
effects of the M2 channel blocker, rimantadine.
In the above experiments, virus was allowed to enter
susceptible cells for 4 h prior to treatment with rimantadine.
We next determined if the rimantadine would interfere with
entry into the susceptible cells. For this experiment, C8166
cells were inoculated with SHIVM2 virus in the presence of 75
AM rimantadine for 4 h. At 4 h, the virus inoculum andrimantadine were removed, the cells washed three times, and
then incubated in fresh medium lacking rimantadine for 7 days.
As shown in Fig. 7D, treatment of cells with rimantadine prior
to and during the 4 h inoculation period had no effect on the
virus replication, indicating that entry was not effected by the
rimantadine.
Electron microscopy reveals an increase in the accumulation of
viral particles at the cell plasma membrane of SHIVM2-infected
cells treated with rimantadine
As the inhibitor studies indicated that rimantadine
inhibited the replication of the virus, we examined the
maturation of the SHIVM2 and parental SHIVKU-1bMC33 in
the presence of 50 AM rimantadine. We chose to examine
infected cells treated with 50 AM rimantadine as this
concentration that exhibited (¨45%) inhibition of SHIVM2
Fig. 8. Macaques inoculated with SHIVM2 develop CD4
+ T cell loss within 1
month of inoculation. (A) Macaques CW8H (.) and CW8F (O) were inoculated
with SHIVM2 and circulating CD4
+ T cells determined at various times post
inoculation. (B) Circulating CD4+ T cell levels in macaques 2000 (.), 2001
(n), CM4G (), and CM4K (r) determined at various times post-inoculation
with parental SHIVKU-1bMC33.
D.R. Hout et al. / Virology 344 (2006) 541–559548release as determined by p27 assays. As shown in Fig. 5B,
the maturation of parental SHIVKU-1bMC33 in C8166 cells
treated with 50 AM rimantadine was comparable to untreated
cultures with a mean number of viral particles per cell being
45.7. Electron microscopy revealed that the mean number of
viral particles per cell was 40 with the majority of the cells
having less than 50 viral particles per cell (Fig. 6C). In
contrast, the maturation of SHIVM2 was considerably altered
in the presence of rimantadine. As shown in Figs. 5D–E,
virus particles appeared to accumulate at the cell surface of
cells with a mean number of viral particles per cell of 104,
which was approximately 2.5 times that observed for the
untreated cells (Fig. 6D). The difference in the number of
particles per cell in untreated and 50 AM treated SHIVM2-
infected cultures was significant (P < 0.001). Electron
microscopy also revealed that particles appeared to be
tethered to the membrane and could be observed maturing
within intracellular vesicles (Fig. 5F). These results suggested
that SHIVM2 release from infected cells was reduced in the
presence of 50 AM rimantadine.
The SHIVM2 infects pig-tailed macaques and causes a rapid
CD4+ T cell loss observed with the parental SHIVKU-1bMC33
To assess whether SHIVM2 was capable of causing CD4
+
T cell loss in macaques, two pig-tailed macaques (CW8F,
CW8H) were inoculated with SHIVM2. CD4
+ T cell counts
and viral loads were then monitored for up to 40 weeks
(Fig. 8A). After inoculation with SHIVM2, the circulating
CD4+ T cell numbers in macaque CW8F dropped from 2865
cells/Al at 1 week post-inoculation to 83 cells/Al at 4 weeks
post-inoculation. The circulating CD4+ T cells in the this
macaque continued to remain low (<100 cells/Al) until the
macaque was euthanized at 24 weeks (circulating CD4+ T
cells at 54 cells/Al) in moribund condition. Similar to
macaque CW8F, macaque CW8H had a high level of
circulating CD4+ T cells at 1 week post-inoculation (2318
cells/Al), which dropped to less than 100 cells/Al by 6 weeks
post-inoculation. Macaque CW8H was euthanized at 40
weeks post-inoculation (CD4+ T cell level at 63 cells/Al) in a
moribund condition. The circulating CD4+ T cell levels were
similar to those observed following inoculation of macaques
with parental SHIVKU-1bMC33, in which there was a severe
drop in the levels of circulating CD4+ T cells within 4
weeks post-inoculation (Fig. 8B) but were in contrast to
those observed following inoculation with SHIVTM (Hout
et al., 2005).
The plasma viral loads in animals inoculated with SHIVM2
were similar to parental SHIVKU-1bMC33
We compared the plasma viral loads in the three macaques
inoculated with SHIVM2 with the viral loads in macaques
inoculated with the parental SHIVKU-1bMC33. As shown in Figs.
9A–B, both macaques inoculated with SHIVM2 had viral loads
that were similar to those from macaques inoculated with the
parental SHIVKU-1bMC33.-The sequence of the vpu gene was stable during the period of
severe CD4+ T cell loss
In order to assess the stability of the vpu gene during the
course of infection, DNA was extracted from PBMC samples
at 2, 6, 12, 20 weeks, and at necropsy. The vpu sequence
was amplified and directly sequenced and compared to the
input vpu sequence of the SHIVM2. As shown in Fig. 10, the
vpu (and in particular, the sequence of the TM domain) was
stable in the vpu sequences amplified through 20 weeks. At
the 24 weeks and at necropsy, a termination codon was
detected in the vpu sequences amplified from the PBMC
DNA isolated from macaque CW8H, which resulted in a
truncation of the predicted Vpu protein to 22 amino acids.
We also analyzed the vpu sequences analyzed from the
mesenteric lymph node, spleen, and thymus at necropsy.
Sequence analysis of the vpu sequences amplified from
isolated mesenteric lymph node and spleen DNA from
CW8H also had a termination codon in the same position
detected in the PBMC while the vpu sequences amplified
from the thymus DNA were identical to the input virus. The
vpu sequences amplified from isolated spleen, mesenteric
Fig. 9. Plasma viral loads in macaques inoculated with SHIVM2 and
SHIVKU-1bMC33. (A) Plasma viral loads in macaques CW8H (.) and CW8F
(O) inoculated with SHIVM2. (B) Plasma viral RNA levels in three
macaques (2000, .; 2001, ˝; and CM4K, r) inoculated with SHIVKU-
1bMC33. Samples were subjected to real-time RT-PCR and Taqman probe
homologous to the SIV gag gene. Standard curves were generated using
five dilutions of viral RNA of known concentration.
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sequence changes.
Isolation of a highly cytopathic virus from the spleen of
macaque CW8H with a truncated Vpu protein
Sequence analysis indicated that the sequence of the VpuM2
protein was truncated starting at 24 weeks post-inoculation.
While performing infectious centers assays at necropsy, we
observed co-culturing isolated spleen cells from CW8H with
the indicator C8166 cell line resulted in massive syncytial
cytopathology that occurred within 1–2 days post-inoculation
with the C8166 cells. Cell-free supernatants from these cultures
were harvested and a series of three limiting dilution assays
using C8166 cells were performed to isolate this strain of virus.
In each of assay, the massive syncytial cytopathology was
again observed. As shown in Fig. 11, this syncytial cytopathol-
ogy was easily visible within 24 h after inoculation of cultures,
which was significantly faster when compared to SHIVM2-
inoculated where syncytia formation usually occurs at approx-
imately 5 days post-inoculation (Fig. 11). DNA was isolated
from cells of the passaged virus and the sequence of the vpuand gp120 region of env determined. Sequence analysis of the
vpu gene revealed a mutation that resulted in a truncated Vpu
protein of 22 amino acids with the UGG codon being mutated
to a UAG (Fig. 10A). Based on this sequence, we predicted that
this virus isolate would be resistant to the actions of
rimantadine. The CW8H spleen virus was grown in C8166
cells in the presence or absence of 100 AM rimantadine. Our
results indicated that the CW8H spleen virus was resistant to
the actions of rimantadine (data not shown). Sequence changes
in the Env are also known to affect the syncytial nature of HIV-
1 and SIV. Thus, we also analyzed the sequence of the gp120
region of env by sequencing the amplified gp120 sequences
from the virus-infected cells. The results indicated 10 amino
acid substitutions in the gp120 when compared to the parental
SHIVKU-1bMC33 (Fig. 10B). Among the amino acid substitu-
tions observed in the SHIVCW8HSPL were the elimination of
two N-linked glycosylation sites.
Macaques inoculated with SHIVM2 developed histopathology
that was similar to the macaques inoculated with parental
SHIVKU-1bMC33
We examined the histological sections from tissues of
macaques at necropsy and compared the lesions to those
observed following inoculation with parental SHIVKU-1bMC33.
No significant histological lesions were observed in the 15
regions of the CNS, the heart, liver, lungs, kidney, or
pancreas. As shown in Fig. 12, the SHIVM2-inoculated
macaques developed severe atrophy of the thymus and lymph
nodes demonstrated little follicular activity and no germinal
centers. The distribution of virus in the various visceral
organs was determined by PCR for viral 2-LTR sequences. As
shown in Table 1, viral 2-LTR sequences were detected in
DNA isolated from 5 of 13 visceral organs from CW8F, and 7
of 13 visceral organs tissues from CW8H. The majority of the
tissue DNAs that were positive for the presence of 2-LTR
sequences were the lymphoid organs. We also analyzed the
DNA samples isolated from 15 regions of the CNS for gag
and 2-LTR sequences (Table 1). Macaques CW8F and CW8H
were positive for gag sequences in 11 of 15 and 10 of 15
regions of the CNS, respectively (data not shown). However,
only one region from macaque CW8F (cerebellum) was
positive for 2-LTR sequences and none from macaque CW8H
(Table 1).
Analysis of viral loads by PCR-ICA is shown in Fig. 13 and
indicates that the viral loads in the SHIVM2-inoculated
macaques were comparable to macaques inoculated with
SHIVKU-1bMC33. The results correlate well with plasma viral
load data, CD4+ T cell loss, and histopathology.
Discussion
The Vpu protein of HIV-1 has two established functions in
virus replication and these include the down-regulation of CD4
from the cell surface and enhancement of virion release from
infected cells. While the molecular mechanisms of the CD4
down-regulation have been determined, much less is known
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virion release has been associated with the TM domain of the
Vpu protein and some investigators have shown that the TM
domain is capable of forming an ion channel (Ewart et al.,
1996; Schubert et al., 1996a). Expression of Vpu in frog
oocytes results in a conductance that is weakly selective for
cations and modeling studies have suggested that a pentamericFig. 10. Sequence analysis of the vpu and env genes amplified from macaques inocu
times post-inoculation, and from the spleen, mesenteric lymph nodes and thymus at n
are the sequence of the parental SHIVKU-1bMC33 and SHIVM2. (*) denotes the presenc
of the predicted amino acid sequences of the gp120 region of Env from parental SH
(SHIVCW8HSPL). The horizontal lines under the sequences indicate the two N-linkestructure for the Vpu TM domain would be optimal for the
formation of such a channel (Grice et al., 1997; Sansom et al.,
1998; Wray et al., 1999; Cordes et al., 2001, 2002; Lopez et al.,
2002). Recently, the structure of the Vpu transmembrane
domain was elucidated by synthesizing the hydrophobic
transmembrane domain along with 12 hydrophilic cytoplasmic
residues for stability and solubility (Park et al., 2003). Thus, thelated with SHIVM2. (A) DNAwas isolated from PBMC of macaques at various
ecropsy. The vpu gene was amplified, isolated, and sequenced. Shown at the top
e of a termination codon resulting in a truncated Vpu sequence. (B) Comparison
IVKU-1bMC33 and the virus isolated from the spleen tissue of macaque CW8H
d glycosylation sites that were eliminated in the SHIVCW8HSPL virus.
Fig. 10 (continued).
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member of a class of proteins known as the viroporins.
Previous studies showed that two derivatives of the Na+ K+
antiporter amiloride, dimethyl amiloride (DMA) and hexam-
ethylene amiloride (HMA), inhibited Vpu-mediated virion
release and replication in macrophages (Ewart et al., 2002,
2004). In the most recent study, both DMA and HMA wereFig. 11. Phase contrast micrographs of a highly cytopathic variant from the spleen o
micrographs of C8166 cells inoculated with SHIVM2 at 1, 3, or 6 days post-inocula
SHIVCW8H at 1, 3, or 6 days post-inoculation. (Bottom row) Phase contrast microgshown to inhibit HIV-1 replication in monocyte-derived
macrophage cultures (Ewart et al., 2004). While these studies
are encouraging that compounds targeting the Vpu function can
reduce virus replication, it is not yet clear whether these
compounds directly target the Vpu protein or if they target
another cellular function used by Vpu. Furthermore, both
DMA and HMA have a ‘‘narrow window of efficacy’’ beforef macaque CW8H that was resistant to rimantadine. (Upper row) Phase contrast
tion. (Middle row) Phase contrast micrographs of C8166 cells inoculated with
raphs of mock-inoculated C8166 cells at 1, 3, or 6 days.
Fig. 12. Pathology associated with SHIVM2 infection. Hematoxylin and eosin stains of sections from the mesenteric lymph node (A, B), and thymus (C, D) from
macaque CW8F (A, C) and an uninoculated macaque (B, D).
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viroporin could substitute for the Vpu TM and if drugs directly
targeting this TM domain could interfere in virus replication.
We chose to insert the M2 protein ion channel because the
structure of the Vpu protein has been modeled after the well
studied M2 protein of influenza A virus (Lamb and Pinto,
1997; Grice et al., 1997; Sansom et al., 1998; Fischer and
Sansom, 2002; Gonzalez and Carrasco, 2003). These two
proteins are similar in their length, orientation in the
membrane, and ability to form oligomeric structures in
membranes. The M2 protein of influenza virus has two
important functions in the influenza A virus replication cycle
(Gonzalez and Carrasco, 2003). During virus entry by receptor-
mediated endocytosis, acidification of endosomes activates the
M2 ion channel resulting in the influx of H+ into the virus
resulting in a low pH conformational change in the hemaglu-
tinin (HA). This results in exposure of the fusion peptide
domain of the HA, fusion of the endosomal and viral
membranes, and release of the viral nucleocapsids into the
cytoplasm. In addition to its role in virus entry, the M2 protein
is important for transport of the HA molecule to the cell
surface. As there is a gradual drop in the pH from the rough
endoplasmic reticulum (RER) to the trans-Golgi network
(TGN), the M2 protein (based on its orientation) becomes
activated and causes an efflux of H+ from the TGN, thereby
preventing a low pH conformational change of the newly
synthesized HA molecule as it transported to the cell surface
(Sakaguchi et al., 1996; Henkel and Weisz, 1998; Henkel et al.,
1999). Finally, there are two well established antiviral drugs,
amantadine and rimantadine, that target the M2 ion channel
and have been used to treat influenza A virus infections in
humans.We chose to insert the gene for this chimeric VpuM2 protein
into the genetic background of the pathogenic molecular clone
SHIVKU-1bMC33 in order to analyze its role in disease caused by
SHIV. Using this pathogenic molecular clone, we recently
reported on the construction of a SHIV in which the amino
acids of TM domain of Vpu were scrambled but kept the
hydrophobic nature of this domain (Hout et al., 2005). When
SHIVTM was inoculated into three pig-tailed macaques, none
developed the severe CD4+ T cell loss or high viral burdens
that are normally observed following inoculation with the
parental SHIVKU-1bMC33 (Hout et al., 2005). Additionally, the
SHIVTM replicated poorly in C8166 cells and had a maturation
pattern that was differed from the parental SHIVKU-1bMC33
(Hout et al., 2005). The results of electron microscopy studies
indicated that SHIVM2 had a maturation pattern that was
similar to that of parental SHIVKU-1bMC33 (Hout et al., 2005).
Furthermore, unlike SHIVTM, SHIVM2 was pathogenic in pig-
tailed macaques with both developing severe CD4+ T cell loss
within 1 month and histological lesions in lymphoid tissues,
which was similar to the parental SHIVKU-1bMC33 virus.
Together, these data indicate that the SHIVM2 was phenotyp-
ically different from SHIVTM.
We showed that the VpuM2 chimeric protein was stable
during the period of severe CD4+ T cell depletion with no
nucleotide substitutions occurring in vpu amplified from
PBMC or lymphoid organs from macaque CW8F at necropsy.
However, we did observe that beginning at 24 weeks the
amplified vpu had a termination codon that truncated the Vpu
protein. Sequence analysis revealed that this became the
predominant genotype in all three lymphoid organs analyzed.
The termination codon occurred at codon 22 (the UGG was
changed to a UAG) that normally encodes for a tryptophan
Table 1
Distribution of viral 2LTR sequences in tissues from macaques inoculated with
SHIVM2a
Tissue Macaque
CW8F CW8H
Visceral organs
Heart () ()
Kidney () ()
Liver () (+)
Lung () (+)
Pancreas () (+)
Salivary gland () ()
Axillary lymph node () ()
Inguinal lymph node (+) ()
Mesenteric lymph node (+) (+)
Small intestine (+) (+)
Spleen (+) (+)
Tonsil () ()
Thymus (+) (+)
CNS
Frontal cortex () ()
Motor cortex () ()
Parietal cortex () ()
Occipital cortex () ()
Temporal cortex () ()
Cerebellum (+) ()
Medulla () ()
Pons () ()
Midbrain () ()
Thalamus () ()
Corpus callosum () ()
Basal ganglia () ()
Cervical spinal cord () ()
Thoracic spinal cord () ()
Lumbar spinal cord () ()
a Tissue DNA samples were analyzed for 2-LTR sequences using nested
DNA PCR as described in the text.
Fig. 13. Virus loads in tissues from macaques inoculated with SHIVKU-1bMC33
and SHIVM2. Cells were isolated from the mesenteric lymph nodes (MES LN),
spleen (SPL), and thymus (THY) and analyzed for the number of viral genome
copies per 106 cells as described in the Materials and methods section.
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act through the interaction of a histidine and tryptophan
residues in the motif His-X-X-X-Trp with the tryptophan
residue of this motif serving as the gate of the M2 proton
channel (Okada et al., 2001; Takeuchi et al., 2003; Tang et al.,
2002; Wang et al., 1995). Thus, in the SHIVCW8HSP virus, the
gate of the ion channel was effectively eliminated and
suggesting that if stably expressed in membranes that this
proton channel might be constitutively open. Alternatively, the
M2 ion channel might be effectively eliminated suggesting that
there was a selection against a virus with a functional M2 ion
channel. Additionally, this virus gained the phenotypic
property of being extremely fusogenic, with cell-free stocks
causing syncytia formation in C8166 cultures within 24 h post-
inoculation. Previous studies have reported that the Vpu
negative viruses result in enhanced syncytia formation (Yao
et al., 1993). Furthermore, other investigators have identified
determinants in the envelope glycoprotein that resulted in
increased fusogenicity in pathogenic SHIV-KB9 (Etemad-
Moghadam et al., 2000). It will be of interest to determine if
the truncation of the Vpu or the amino acid substitutions within
the gp120 region of Env contributes to this enhanced
fusogenicity of this virus isolate.As these results suggest that the function imparted by the
TM domain of Vpu can be substituted with the same region
from the M2 protein of influenza A virus, the obvious
question that arises is ‘‘How does the M2 TM positively
affect the maturation of the SHIV?’’ The finding that
rimantadine did not affect virus production when used at
the early stages of virus entry suggests that the M2 protein is
probably exerting its effects at the level of virus maturation.
Previous studies have shown that the TM domain of the Vpu
protein is involved in the enhanced release function (Klimkait
et al., 1990; Schubert et al., 1996b). One possibility is that the
structure of these two TM domains may have more
‘‘commonality’’ than previously envisioned. It is quite
possible that the M2 TM with its ion channel properties
may modify the local environment that is conducive for the
maturation of this SHIV from cells. Finally, electron
microscopic examination of SHIVM2-infected cells that were
treated with 50 AM rimantadine, a concentration that reduced
release of viral p27 by approximately 50%, revealed an
accumulation of viral particles at the cell plasma membrane
and within intracellular vesicles. The finding that a 50 AM
concentration rimantadine caused an alteration in the virus
maturation pattern that was similar to that reported for Vpu
() HIV-1 suggests that the M2 ion channel may be acting
through a similar mechanism as the TM of the native Vpu.
Taken together, these data provide evidence that the chimeric
VpuM2 protein was active and that inhibitors targeting the M2
ion channel could reduce release of SHIVM2 from infected
cells. As SHIVM2 was inhibited by rimantadine, it will be of
interest to determine if administration of rimantadine to
macaques can reduce viral loads and disease. If successful,
it would provide direct in vivo evidence that the Vpu protein
and specifically the TM domain of the Vpu protein are novel
targets for anti-HIV-1 drugs.
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Cells, plasmids, and viruses
The lymphocyte C8166 cell line was used for transfections
as well as indicator cells to measure infectivity and
cytopathicity of the viruses used in this study. C8166 cells
were maintained in RPMI-1640, supplemented with 10 mM
HEPES buffer pH 7.3, 2 mM glutamine, 5 Ag per ml
gentamicin, and 10% fetal bovine serum (R10FBS). The
derivation of SHIVKU-1bMC33 has been previously described
(McCormick-Davis et al., 2000; Stephens et al., 2002). The
construction and characterization have been previously
described (Hout et al., 2005). The plasmids expressing the
subtype B Vpu fused to the EGFP (pcvpuEGFP) have been
previously described (Singh et al., 2003; Gomez et al., 2005;
Pacyniak et al., 2005). Subcellular marker plasmids used in
these studies include DsRed2-ER (catalog number 632409;
fusion of the targeting signal of calreticulin), pECFP-Golgi
(catalog number 632357; fusion with Golgi resident protein h
1,4 galactosyltransferase), and pECFP-Mem (catalog number
632360; fusion of the N-terminal 20 amino acids of
neuromodulin or GAP-43, which has a palmityolation signal),
which were obtained from Clontech (Palo Alto, Ca). The
ECFP-Mem is a marker for membranes including the cell
plasma membrane.
Construction of the SHIVM2
A virus SHIVM2 was constructed in which the TM sequence
of Vpu (VAIVALVVAIIIAIVVWSI) was replaced with
the TM sequence (PLVIAASIIGILHLILWIF) from the M2
protein of influenza A virus in the parental SHIVKU-1bMC33.
Plasmid pUC19DSNvpu12, containing the SphI to KpnI
fragment of SHIVKU-1bMC33 in pUC-19 (and coding for the
tat, rev, vpu, and 5V end of env) was used for the site-directed
mutagenesis studies of the Vpu TM. The plasmid used was
pUC19DSNvpu12 and the Quick-Change Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions. A
total of 17 site-directed mutagenesis reactions were performed
to alter the Vpu TM sequence to the that of the M2 protein.
Clones were isolated, plasmids isolated, and the entire insert
sequenced to determine if the mutations were introduced as
expected and to ensure that no additional changes were
introduced during the mutagenesis step. The plasmid, desig-
nated as pUC19DSNvpuM2, was digested to completion with
SphI and KpnI, the 450 base pair insert isolated and ligated into
p3VSHIVKU1-bMC33 using T4 DNA ligase, which was also
digested with KpnI and SphI and gel purified. The resulting
plasmid, p3VSHIVM2, was sequenced to insure that no
insertions or deletions had occurred during the cloning process.
The SHIVM2 virus was generated by digestion of p5V-SHIV-4
and p3VSHIVM2 with SphI, ligation of the two plasmids
together with T4 DNA ligase, and transfection into C8166
cells as previously described (McCormick-Davis et al., 2000;
Stephens et al., 2002; Hout et al., 2004a, 2005). Stocks of virus
were prepared and stored at 86 -C.Construction of VpuM2EGFP
In order to assess the intracellular transport of the VpuM2
and its ability to down-regulate CD4 expression, we cons-
tructed an expression vector in which the VpuM2 was fused to
the gene for EGFP using the same methodology as we used to
express the subtype B, C proteins of HIV-1 as well as four
SIVcpz Vpu proteins (Singh et al., 2003; Pacyniak et al., 2005;
Gomez et al., 2005; Hout et al., 2005).
Transfections and laser scanning confocal fluorescence
microscopy analysis
Plasmids expressing VpuEGFP and other fusion proteins
were transfected in human 293 cells to assess their subcellular
localization using a cationic polymer (polyethylenimine)
transfection reagent (ExGen 500, MBI Fermentas) using the
manufacturer’s protocol. Briefly, 1–3  105 cells were seeded
onto cover slips in each well of a 6 well tissue culture plate
24 h prior to transfection. Transfection was carried out on
cultures that were 50–60% confluent using 4.75 Ag plasmid
DNA and 15.5 Al of ExGen 500 corresponding to 6
equivalents. Each plasmid DNA sample was diluted in 300
Al of 150 mM sodium chloride solution separately. Samples
were vortexed gently and immediately centrifuged at low
revolution for a few seconds. Polyethylenimine was then
added to the plasmid DNA solution, mixed with a vortex, and
allowed to stand at room temperature for 10 min. The 293 cells
were washed with serum-free media twice and 3.0 ml of
serum-free DMEM was added. Polyethylenimine/DNA mix-
ture was added to the cells and the plate swirled by slow hand
rotation for a couple of seconds. Culture plates were
centrifuged at 280  g for 5 min and incubated at 37 -C for
30 min. The medium from transfected cultures was replaced
with fresh complete growth media and cells were incubated at
37 -C in 5% CO2 atmosphere. Transfected cells were observed
by confocal microscopy, which is known to have the
advantage that fluorescence can be detected from cells in
different optical sections. Transfected cells were grown in 35
mm Petri dishes, and were prepared for confocal microscopy
as follows. Cells were rinsed briefly in phosphate buffered
saline (PBS, pH 7.2) at room temperature. The cells were fixed
in freshly prepared, ice cold, 1% paraformaldehyde in 0.13 M
in sodium phosphate pH 7.2 for 2 min. The fixative was
removed and the cells briefly rinsed in phosphate buffered
saline. The saline was removed, and one drop of mounting
media was placed on each dish. The mounting media are
composed of 75% glycerol, 25% 0.13 M sodium phosphate
buffer pH 8.0 plus 0.02% n-propyl gallate. A square number
one glass cover slip was placed over each dish. The cells were
imaged with a Zeiss LSM 510 confocal microscope in the
upright configuration. The objective used was a 63  1.4 n.a.
Plan Apochromat. Images were captured at 12 bit resolution
with a pixel array of 1024  1024 and a zoom of 2.0. The
signal was averaged 4 times per line. The EGFP was excited
with light at 488 nm (laser intensity 75% for all images), and
the emitted light was collected after passing through a 505 nm
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all images. The detector gain was decreased from 692 nm to
618 nm for cells expressing VpuSCEGFP1 since the intensity
of the signal resulted in saturation. A Z stack of 20 optical
slices was obtained so that the entire cell was imaged from
bottom to top. The pinhole was set to 96 Am which at this
wavelength represents one airy unit. The optical section had a
width of 0.7 Am. Simultaneous to the acquisition of the
confocal signal from the EGFP, a non-confocal transmitted
light image was obtained to provide a reference point for the
EGFP signal. Individual confocal slices were overlaid onto the
greyscale transmitted light image.
To confirm the presence of the Vpu fusion protein at
different subcellular compartments, a series of co-transfection
studies were performed using vectors expressing either an ER
marker fused to the fluorescent protein DsRed2 (pDsRed2-
ER), a Golgi complex marker fused to a cyano-variant of
EGFP(pECFP-Golgi), or a membrane marker (pECFP-Mem).
293 cells were co-transfected with vectors expressing the
various Vpu fusion proteins and either DsRed2-ER, ECFP-
Golgi, or ECFP-Mem. At 48 h post-transfection, cells were
processed for confocal microscopy as described above, and
cells identified expressing both proteins. Fluorescent digital
images were obtained using a Zeiss LSM510 confocal
microscope equipped with an Argon/2 laser (25 mW) for the
excitation (488 nm, 50% laser power) and detection (band pass
505–530 nm filter; BP505-530) of EGFP, for the excitation
(458 nm, 100% laser power) and detection (band pass 475–525
nm filter; BP475-525) of ECFP, and for excitation (558 nm,
100% laser power) and detection (band pass 583 nm filter;
LP560) of DsRed2. Images were acquired in Multitrack
channel mode (sequential excitation/emission) with LSM510
(v 3.2) software and a Plan-Apochromat 100/1.4 Oil DIC
objective with frame size of 2048  2048 pixels. Detector gain
was set initially to cover the full range of all the samples and
background corrected by setting the amplifier gain, and all
images were then collected under the same photomultiplier
detector conditions and pinhole diameter.
Assays for detection of cell surface CD4 and degradation of
CD4
To determine if the VpuM2EGFP construct was capable of
promoting degradation of CD4 in transfected cells, we
employed HeLa CD4+ cells. Cultures of HeLa CD4+ in which
approximately 80–85% of the cells stained positive for surface
CD4 were recloned to obtain a population of cells in which
>99% of the cells stained positive for cell surface CD4.
Briefly, HeLa CD4+ cells were grown on cover slips and
transfected with pcvpuEGFP as described earlier. At 48 h post-
transfection, cells were washed twice with wash buffer (PBS
pH 7.2, containing 2% fetal calf serum and 0.01% NaN3) and
reacted with mouse anti-CD4 (clone SFCI12T4D11CD4,
Beckman-Coulter, 1:500 dilution) for 45 min. After the
incubation, cover slips were washed three times and incubated
with rhodamine-conjugated secondary antibody (goat anti-
mouse, Chemicon, 1:50 dilution) for 35 min followed bywashing five times in buffer without serum. Cells were then
fixed in 1% formalin for 10 min, washed twice, equilibrated
with anti-fade buffer, and mounted on microscope glass slides
using Anti-fade (Molecular Probes, Oregon). Cells were
immediately observed under a laser scanning confocal
microscopy with appropriate filters for visualization of EGFP
and CD4 staining. All the staining procedures were performed
on ice and in the dark. HeLa CD4+ cells transfected with
EGFP alone served as control for down-regulation of CD4 and
cultures of HeLa CD4+ cells treated with wash buffer instead
of primary antibody served as negative control for CD4
staining. A minimum of 400 EGFP expressing cells were
counted.
In addition to detection of CD4 on the cell surface of
transfected HeLa CD4+ cells, co-transfection experiments were
performed using vectors expressing each VpuEGFP fusion
protein and a vector expressing the human CD4 protein
(pCMV4Neo; Goldsmith et al., 1995). Cells were transfected
with Vpu fusion and pCMV4Neo vectors at a 3:1 ratio,
respectively. This was to insure that all cells transfected with
the CD4 expressing vector were also transfected with the
vector expressing the Vpu fusion proteins. At 48 h post-
transfection, cells were starved for methionine and then
radiolabled with 500 ACi 35S-methionine/cysteine for 1 h.
The radiolabel was removed and chased with 100 cold
methionine/cysteine for 4 h. Cells were lysed in RIPA buffer,
lysates prepared, and the CD4 immune precipitated using a
rabbit anti-CD4 (sc-7219; Santa Cruz Biotechnology) and
protein A Sepharose (PAS). Immune precipitates were collect-
ed, washed three times with 1 RIPA, and analyzed by SDS-
PAGE (10% gel). Controls included co-transfection with
pcEGFP (expressing on EGFP) as negative control for CD4
degradation and co-transfection with a pcvpuEGFP (expressing
the subtype B VpuEGFP fusion protein) as a positive control
for CD4 degradation.
Immunoprecipitation of Vpu proteins
To determine if Vpu proteins were expressed in SHIVM2-
inoculated cultures, C8166 cells were inoculated with 103
TCID50 of either SHIVM2 or SHIVKU-1bMC33. At 5 days post-
infection, the medium was removed and infected cells were
incubated in methionine/cysteine-free Dulbecco’s modified
Eagle’s medium (DMEM) for 2 h. The cells were then
radiolabeled for 12 h with 500 ACi per ml of 35S-Translabel
(methionine and cysteine, ICN Biomedical, Costa Mesa, CA).
Vpu proteins were immunoprecipitated from the cell lysates
using an anti-Vpu serum as described previously (McCormick-
Davis et al., 2000; Singh et al., 2003) prior to incubation with
antiserum. Lysates were centrifuged in a microfuge to remove
nuclei prior to the addition of antibody. Cell lysates were
incubated with antibody for 16 h at 4 -C and immunopreci-
pitates were collected on protein A Sepharose. The beads were
washed three times with RIPA buffer, and the samples were
resuspended in sample reducing buffer and boiled. Proteins
were analyzed by SDS-PAGE and visualized by standard
autoradiographic techniques.
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To analyze the viral proteins synthesized and released from
cells, C8166 cells were inoculated with 104 TCID50 of either
SHIVM2 or SHIVKU-1bMC33. At 7 days post-inoculation, the
medium was removed and infected cells were incubated in
methionine/cysteine-free Dulbecco’s modified Eagle’s medium
(DMEM) for 2 h. The cells were then radiolabeled for 30 min
with 1 mCi per ml of 35S-Translabel (methionine and cysteine,
ICN Biomedical, Costa Mesa, CA) and the radiolabel chased for
various periods of time in DMEM containing 100 unlabeled
methionine/cysteine. SHIV proteins were immunoprecipitated
from the cell culture medium and infected cell lysates using
plasma pooled from several rhesus monkeys infected previously
with non-pathogenic SHIV-4. Briefly, the cell culture medium
was clarified (16,000  g) for 2 min. The supernatant was
transferred and made 1 with respect to cell lysis buffer (50
mM Tris–HCl, pH 7.5; 50 mMNaCl; 0.5% deoxycholate; 0.2%
SDS; 10 mM EDTA) and SHIV proteins were immunopreci-
pitated with 10 Al of a pooled serum from several monkeys that
were inoculated with non-pathogenic SHIV for over 1 year. For
immunoprecipitation of cell associated SHIV proteins, cell
lysates were prepared as described previously (Stephens et al.,
1995, 1997; McCormick-Davis et al., 2000; Hout et al., 2004a,
2005) prior to incubation with antiserum. Lysates were
centrifuged in a microfuge to remove nuclei prior to the
addition of antibody. Cell lysates and culture medium were
incubated with antibody for 16 h at 4 -C. All immunoprecipi-
tates were collected on protein A Sepharose, the beads washed
three times with RIPA buffer, and the samples resuspended in
sample reducing buffer. Samples were boiled and the SHIV
specific proteins analyzed by SDS-PAGE. Proteins were then
visualized by standard autoradiographic techniques.
p27 assays
p27 growth curves assays were used to assess replication
kinetics of the SHIVM2 or parental SHIVKU-1bMC33. Cultures of
106 C8166 cells were inoculated with equivalent amounts (10
ng) of cell-free virus stocks for 2 h. At the end of 2 h, the cells
were centrifuged at 400  g for 10 min and the pellet washed
with 10 ml of medium. This was repeated two additional times.
The cells were resuspended in RPMI-1640 supplemented with
10% FBS and antibiotics and this was considered the 0 time
point of the assay. Cultures were incubated at 37 -C and aliquots
of the culture were removed at 0, 1, 3, 5, 7, and 10 days. The
culture medium was separated from the cells by centrifugation
and the culture supernatants assayed for p27 according to the
manufacturer’s instructions. For assays involving rimantadine,
the drug was freshly prepared in RPMI-1640 medium as 10 mM
stocks and filter sterilized prior to addition to cultures. Drug was
added to cultures at the 0, 3, and 6 day time points.
Electron microscopy
To determine the site of intracellular maturation, infected
cells were examined by electron microscopy. Cultures ofC8166 cells were inoculated with SHIVKU-1bMC33 or SHIVM2
at a multiplicity of infection of 0.01. Cells were incubated for 7
days at which time cells were pelleted at 400  g for 10 min.
Cells were washed three times with 10 ml of phosphate
buffered saline (pH7.4) and then fixed in 2% glutaraldehyde
overnight at 4 -C. Cells were post-fixed in 1% osmium
tetroxide (OsO4) for 1 h. The cells were washed twice with
water and dehydrated through a series of alcohols (30–100%)
followed by embedding in Embed 812 resin. Thin sections
were cut at 80 A, stained with uranyl acetate and lead citrate,
and examined under a JEOL 100CXII transmission electron
microscope. The number of virus particles associated with 100
infected cells (either at the surface or within the cell) was
enumerated. Data were analyzed by planned comparisons using
unpaired t test. Data from the untreated and 50 AM treated
SHIVM2-infected cultures or SHIVKU-1bMC33-infected cultures
were compared.
Macaques analyzed in this study
Two 1–1.5 year old pig-tailed macaques (Macaca nemes-
trina; CW8F, CW8H) were inoculated intravenously with 1 ml
of undiluted supernatant from C8166-grown stocks of virus
containing 104 TCID50 per milliliter. The inoculated macaques
were compared to macaques inoculated with parental patho-
genic SHIVKU-1bMC33 and those inoculated with SHIVTM as
previously described (Stephens et al., 2002; Hout et al., 2005).
The animals were housed in the AAALAC-approved animal
facility at the University of Kansas Medical Center. Heparinized
blood was collected weekly for the first 4 weeks, then at 2 week
intervals for the next month, and thereafter at monthly intervals.
Assays for circulating CD4+ T cells
Alterations in the levels of CD4+ lymphocytes after
experimental inoculations were monitored sequentially by
FACS analysis (Becton Dickinson). T lymphocyte subsets
were labeled with OKT4 (CD4; Ortho Diagnostics Systems,
Inc), SP34 (CD3; Pharmingen), or FN18 (CD3; Biosource
International) monoclonal antibodies. T lymphocyte subsets
from a normal uninfected macaque were always performed at
the same time as inoculated macaques as a control for the
FACS analysis.
Processing of tissue samples at necropsy
At the time of euthanasia, all animals in this study were
anesthetized by administration of 10 mg/kg ketamine (IM)
followed by an intravenously administration of sodium
phenobarbital at 20–30 mg/kg. A laparotomy was performed
and the animal exsanguinated by aortic canulation and perfused
with 1 l of cold Ringer’s saline. All aspects of the animal
studies were performed according to the institutional guidelines
for animal care and use at the University of Kansas Medical
Center. Lymphoid tissues (lymph nodes, spleen, and thymus)
and non-lymphoid tissues (brain, heart, kidneys, liver, lungs,
pancreas, small intestine) were obtained and aliquots of tissue
D.R. Hout et al. / Virology 344 (2006) 541–559 557snap frozen for DNA and RNA assays. Portions of lymphoid
tissues were immersed in HBSS to quantify levels of infectious
virus in tissues.
Sequence analysis of the vpu gene
The vpu was amplified from several tissue DNA samples
taken at necropsy to examine the structure of vpu. For
amplification of the vpu, we used oligonucleotide primers 5V-
CCTAGACTAGAGCCCTGGAAGCATCC-3V (sense) and 5V-
GTACCTCTGTATCATATGCTTTAGCAT-3V (antisense),
which are complementary to nucleotides 5845–5870 and
6393–6420 of the HIV-1 (HXB2) genome (Ratner et al.,
1985), respectively. One microgram of genomic DNAwas used
in the PCR with Taq DNA polymerase and the conditions
described above. For the second round of amplification, we
used oligonucleotide primers 5V-TTAGGCATCTCCTATGG-
CAGGAAGAAG-3V (sense) and 5V-CACAAAATAGAGTGG-
TGGTTGCTTCCT-3V (antisense), which are complementary to
nucleotides 5956–5984 and 6386–6413 of the HIV-1 (HXB2)
genome (Ratner et al., 1985), respectively. The conditions for
amplification were identical to those described above. For
sequence analysis, the PCR products from three separate
PCRs were separated by electrophoresis in a 1% agarose
gel, isolated, and each PCR reaction directly sequenced.
Cycle sequencing reactions using the BigDye Terminator
Cycle Sequencing Ready Reaction Kit with AmpliTaq
DNA polymerase, FS (PE Applied Biosystems, Foster
City, CA) and sequence detection were conducted with an
Applied Biosystems 377 Prism XL automated DNA
sequencer and visualized using the ABI Editview program.
Sequences were compared to the intact sequences from
SHIVKU-1bMC33. Sequences showing differences were con-
firmed by molecularly cloning the PCR fragments into
pGEM-T EZ vector followed by sequencing as described
above.
PCR amplification of viral sequence from tissues
SHIV gag
DNA extracted from the visceral organs and different
regions of the CNS as previously described (McCormick-
Davis et al., 2000) was used to amplify viral gag sequences.
The oligonucleotides used for the first round of amplification
were 5V-GATGGGCGTGAGAAACTCCGTCTT-3V(sense) and
5V-CCTCCTCTGCCGCTAGATGGTGCTGTTG-3V (antisense)
corresponding to the regions 1052–1075 and 1423–1450 of
the SIVmac239 gag gene, respectively (Regier and Desrosiers,
1990). The nested SIVmac239 primers used were 5V-GTTGAA-
GCATGTAGTATGGGCAGC-3V (sense) and 5V-CACCAC-
TAGGTGTCTCTGCACTATCTG-3V (antisense) which are
complementary to bases 1142–1165 and 1356–1382 of
SIVmac239, respectively.
Long terminal repeat circles
We examined tissue DNA samples for the presence of 2-
LTR circular DNA (Zazzi et al., 1997; Teo et al., 1997;Sharkey and Stevenson, 2001; Sharkey et al., 2000). DNA
isolated from visceral organs and 12 regions of the brain was
analyzed for the presence of 2-LTR circular forms of DNA as
previously described (McCormick-Davis et al., 2000). The
oligonucleotides used in the first round were 5V-CCTCCTGT-
GCCTCATCTGATACATTTAC-3V (U5 region) and 5V-
ATTTCGCTCTGTATTCAGTCGCTCTGC-3V (U3 region),
which correspond to bases 10,335 to 10,361 and 180 to
153 of the SHIV genome, respectively. The PCR amplifica-
tion was performed using the following conditions: denatur-
ation at 92 -C for 1 min, annealing at 55 -C for 1 min, and
primer extension at 72 -C for 3 min. One microliter of the
first PCR product was used as a template for a second
amplification using the same conditions. The oligonucleotides
primers used for the second round were 5V-TTGGGTATC-
TAATTCCTGGTCCTGAG-3V (U5 region) and 5V-AGGTTC-
TCTCCAGCACTAGCAGGTAGAGC-3V (U3 region; oppoQ
site strand; 456), which correspond to bases 10,389 to 10,417
and 120 to 95 of the SHIV genome, respectively. The
predicted product of the 2-LTR PCR product is 361 base
pairs.
Analysis of virus loads in macaques
PCR-ICA
The virus loads in the CNS and lymphoid tissues were
determined using a quantitative PCR assay modified from a
PCR-infected cell assay previously described (Joag et al.,
1994; Stephens et al., 1998). In this assay, 1 Ag of total cellular
DNA isolated from tissues was subjected to a series of 10-fold
dilutions such that samples contained from 100 ng to 10 fg
(less than one copy of chromosomal DNA). These samples
were used in nested PCR reactions that amplified either the h-
actin gene of the cell (a single copy gene) or the gag gene
from SHIVKU1bMC33. Amplification of either gene using the
primers previously described was shown to detect one of the
copy of each gene (Joag et al., 1994). Thus, amplification of
the h-actin gene determined the number of genome equiva-
lents in each sample, whereas amplification with the gag
primers determined the number of viral copies per number of
genome equivalents. The values were expressed as the number
of viral copies per 106 genome equivalents.
Plasma virus loads
Plasma viral RNA loads were determined on RNA
extracted from 500 Al of EDTA-treated plasma. Virus was
pelleted and RNA extracted using the Qiagen viral RNA kit
(Qiagen, Valencia, CA). RNA samples were analyzed by
real-time RT-PCR using gag primers and a 5VFAM and
3VTAMRA labeled Taqman probe that was homologous to
the SIV gag gene as previously described (Hofmann-
Lehmann et al., 2000). Standard curves were prepared using
a series of six 10-fold dilutions of viral RNA of known
concentration. The sensitivity of the assay was 100 RNA
equivalents per milliliter. Samples were analyzed in triplicate
and the number of RNA equivalents was calculated per
milliliter of plasma.
D.R. Hout et al. / Virology 344 (2006) 541–559558Acknowledgments
The work reported here is supported by NIH grants
AI51981 and AA13845 to E.B.S. The anti-Vpu serum and
the HeLa CD4+ cell line were kindly provided by the NIH
AIDS Research and Reference Reagent Program. We thank
members of the KUMC Biotechnology Support Facility for
their assistance with the sequence analysis and oligonucleotide
synthesis.
References
Barlow, K.L., Ajao, A.O., Clewley, J.P., 2003. Characterization of a novel
simian immunodeficiency virus (SIVmonNG1) genome sequence from a
mona monkey (Cercopithecus mona). J. Virol. 77, 6879–6888.
Cohen, E.A., Terwilliger, E.F., Sodroski, J.G., Haseltine, W.A., 1988.
Identification of a protein encoded by the vpu gene of HIV-1. Nature 334,
532–534.
Cordes, F.S., Kukol, A., Forrest, L.R., Arkin, I.T., Sansom, M.S., Fischer, W.B.,
2001. The structure of the HIV-1 Vpu ion channel: modelling and
simulation studies. Biochim. Biophys. Acta 1512, 291–298.
Cordes, F.S., Tustian, A.D., Sansom, M.S., Watts, A., Fischer, W.B., 2002.
Bundles consisting of extended transmembrane segments of Vpu from HIV-
1: computer simulations and conductance measurements. Biochemistry 41,
7359–7365.
Courgnaud, V., Salemi, M., Pourrut, X., Mpoudi-Ngole, E., Abela, B., Auzel,
P., Bibollet-Ruche, F., Hahn, B., Vandamme, A.M., Delaporte, E., Peeters,
M., 2002. Characterization of a novel simian immunodeficiency virus with
a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans)
provides new insights into simian/human immunodeficiency virus phylo-
geny. J. Virol. 76, 8298–8309.
Courgnaud, V., Abela, B., Pourrut, X., Mpoudi-Ngole, E., Loul, S., Delaporte,
E., Peeters, M., 2003. Identification of a new simian immunodeficiency
virus lineage with a vpu gene present among different cercopithecus
monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J. Virol.
77, 12523–12534.
Etemad-Moghadam, B., Sun, Y., Nicholson, E.K., Fernandes, M., Liou, K.,
Gomila, R., Lee, J., Sodroski, J., 2000. Envelope glycoprotein determinants
of increased fusogenicity in a pathogenic simian–human immunodefi-
ciency virus (SHIV-KB9) passaged in vivo. J. Virol. 74, 4433–4440.
Ewart, G.D., Sutherland, T., Gage, P.W., Cox, G.B., 1996. The Vpu protein of
human immunodeficiency virus type 1 forms cation-selective ion channels.
J. Virol. 70, 7108–7115.
Ewart, G.D., Mills, K., Cox, G.B., Gage, P.W., 2002. Amiloride derivatives
block ion channel activity and enhancement of virus-like particle budding
caused by HIV-1 protein Vpu. Eur. Biophys. J. 31, 26–35.
Ewart, G.D., Nasr, N., Naif, H., Cox, G.B., Cunningham, A.L., Gage, P.W.,
2004. Potential new anti-human immunodeficiency virus type 1 compounds
depress virus replication in cultured human macrophages. Antimicrob.
Agents Chemother. 48, 2325–2330.
Fischer, W.B., Sansom, M.S., 2002. Viral ion channels: structure and function.
Biochim. Biophys. Acta 1561, 27–45.
Fujita, K., Omura, S., Silver, J., 1997. Rapid degradation of CD4 in cells
expressing human immunodeficiency virus type 1 Env and Vpu is blocked
by proteasome inhibitors. J. Gen. Virol. 78, 619–625.
Goldsmith, M.A., Warmerdam, M.T., Atchison, R.E., Miller, M.D., Greene,
W.C., 1995. Dissociation of the CD4 down-regulation and viral infectivity
enhancement functions of human immunodeficiency virus type 1 Nef.
J. Virol. 69, 4112–4121.
Gomez, L.M., Pacyniak, E., Mulcahy, E.R., Flick, M., Gomez, M., Nerrient, E.,
Ayouda, A., Santiago, M., Hahn, B., Stephens, E.B., 2005. Vpu mediated
CD4 down-regulation and degradation is conserved among highly divergent
SIVcpz strains. Virology 335, 46–60.
Gonzalez, M.E., Carrasco, L., 2001. Human immunodeficiency virus type 1
VPU protein affects Sindbis virus glycoprotein processing and enhances
membrane permeabilization. Virology 279, 201–209.Gonzalez, M.E., Carrasco, L., 2003. Viroporins. FEBS Lett. 552, 28–34.
Grice, A.L., Kerr, I.D., Sansom, M.S., 1997. Ion channels formed by
HIV-1 Vpu: a modelling and simulation study. FEBS Lett. 405,
299–304.
Hay, A.J., Zambon, M.C., Wolstenholme, A.J., Skehel, J.J., Smith, M.H., 1986.
Molecular basis of resistance of influenza A viruses to amantadine.
J. Antimicrob. Chemother. 18, 19–29.
Henkel, J.R., Weisz, O.A., 1998. Influenza virus M2 protein slows traffic along
the secretory pathway. pH perturbation of acidified compartments affects
early Golgi transport steps. J. Biol. Chem. 273, 6518–6524.
Henkel, J.R., Popovich, J.L., Gibson, G.A., Watkins, S.C., Weisz, O.A., 1999.
Selective perturbation of early endosome and/or trans-Golgi network pH
but not lysosome pH by dose-dependent expression of influenza M2
protein. J. Biol. Chem. 274, 9854–9860.
Hofmann-Lehmann, R., Swenerton, R.K., Liska, V., Leutenegger, C.M., Lutz,
H., McClure, H.M., Ruprecht, R.M., 2000. Sensitive and robust one-tube
real-time reverse transcriptase-polymerase chain reaction to quantify SIV
RNA load: comparison of one- versus two-enzyme systems. AIDS Res.
Hum. Retroviruses 16, 1247–1257.
Hout, D.R., Mulcahy, E.R., Pacyniak, E., Gomez, L.M., Gomez, M.,
Stephens, E.B., 2004a. Vpu: A multifunctional protein that enhances the
pathogenesis of human immunodeficiency virus type 1. Cur. HIV-1 Res.
2, 255–270.
Hout, D.R., Gomez, M.L., Pacyniak, E., Mulcahy, E.R., Gomez, L.M., Jackson,
M., Flick, M., Fegley, B., McCormick, C., Wisdom, B.J., Culley, N.,
Pinson, D.M., Powers, M., Wong, S.W., Stephens, E.B., 2004b. Fusion of
the upstream vpu sequences to the env of simian human immunodeficiency
virus (SHIVKU-1bMC33) results in the synthesis of two envelope
precursor proteins, increased numbers of virus particles associated with
the cell surface and is pathogenic for pig-tailed macaques. Virology 323,
91–107.
Hout, D.R., Gomez, M.L., Pacyniak, E., Gomez, L.M., Inbody, S.H., Mulcahy,
E.R., Culley, N., Pinson, D.M., Powers, M.F., Wong, S.W., Stephens, E.B.,
2005. Scrambling of the amino acids within the transmembrane domain of
Vpu results in a simian–human immunodeficiency virus (SHIVTM) that is
less pathogenic for pig-tailed macaques. Virology 339, 56–69.
Huet, T., Cheynier, R., Meyerhans, A., Roelants, G., Wain-Hobson, S., 1990.
Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature
345, 356–359.
Joag, S.V., Stephens, E.B., Adams, R.J., Foresman, L., Narayan, O., 1994.
Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques:
effects of splenectomy on virus burden. Virology 200, 436–446.
Klimkait, T., Strebel, K., Hoggan, M.D., Martin, M.A., Orenstein, J.M., 1990.
The human immunodeficiency virus type 1-specific protein vpu is required
for efficient virus maturation and release. J. Virol. 64, 621–629.
Lamb, R.A., Pinto, L.H., 1997. Do Vpu and Vpr of human immunodeficiency
virus type 1 and NB of influenza B virus have ion channel activities in the
viral life cycles? Virology 229, 1–11.
Lopez, C.F., Montal, M., Blasie, J.K., Klein, M.L., Moore, P.B., 2002.
Molecular dynamics investigation of membrane-bound bundles of the
channel-forming transmembrane domain of viral protein U from the human
immunodeficiency virus HIV-1. Biophys. J. 83, 1259–1267.
McCormick-Davis, C., Dalton, S.B., Hout, D.R., Singh, D.K., Berman, N.E.,
Yong, C., Pinson, D.M., Foresman, L., Stephens, E.B., 2000. A molecular
clone of simian–human immunodeficiency virus (DvpuSHIVKU-1bMC33)
with a truncated, non-membrane-bound vpu results in rapid CD4+ T cell
loss and neuroAIDS in pig-tailed macaques. Virology 272, 112–126.
Okada, A., Miura, T., Takeuchi, H., 2001. Protonation of histidine and
histidine– tryptophan interaction in the activation of the M2 ion channel
from influenza a virus. Biochemistry 40, 6053–6060.
Pacyniak, E., Gomez, M.L., Mulcahy, E.R., Jackson, M.J., Hout, D.R.,
Wisdom, B.J., Stephens, E.B., 2005. Identification of a region within the
cytoplasmic domain of the subtype B Vpu protein of human immunode-
ficiency virus type 1 (HIV-1) that is responsible for retention in the Golgi
complex and its absence in the Vpu protein from subtype C HIV-1. AIDS
Res. Hum. Retroviruses 21, 379–394.
Park, S.H., Mrse, A.A., Nevzorov, A.A., Mesleh, M.F., Oblatt-Montal, M.,
Montal, M., Opella, S.J., 2003. Three-dimensional structure of the channel-
D.R. Hout et al. / Virology 344 (2006) 541–559 559forming trans-membrane domain of virus protein ‘‘u’’ (Vpu) from HIV-1.
J. Mol. Biol. 333, 409–424.
Paul, M., Jabbar, M.A., 1997. Phosphorylation of both phosphoacceptor sites in
the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER
degradation of CD4. Virology 232, 207–216.
Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F.,
Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., et al., 1985.
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313,
277–284.
Regier, D.A., Desrosiers, R.C., 1990. The complete nucleotide sequence of a
pathogenic molecular clone of simian immunodeficiency virus. AIDS Res.
Hum. Retroviruses 6, 1221–1231.
Sakaguchi, T., Leser, G.P., Lamb, R.A., 1996. The ion channel activity of the
influenza virus M2 protein affects transport through the Golgi apparatus.
J. Cell Biol. 133, 733–747.
Sansom, M.S., Forrest, L.R., Bull, R., 1998. Viral ion channels: molecular
modeling and simulation. Bioessays 20, 992–1000.
Schubert, U., Henklein, P., Boldyreff, B., Wingender, E., Strebel, K.,
Porstmann, T., 1994. The human immunodeficiency virus type 1 encoded
Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52
and Ser56 within a predicted alpha–helix– turn–alpha–helix–motif.
J. Mol. Biol. 236, 16–25.
Schubert, U., Ferrer-Montiel, A.V., Oblatt-Montal, M., Henklein, P., Strebel,
K., Montal, M., 1996a. Identification of an ion channel activity of the Vpu
transmembrane domain and its involvement in the regulation of virus
release from HIV-1-infected cells. FEBS Lett. 398, 12–18.
Schubert, U., Bour, S., Ferrer-Montiel, A.V., Montal, M., Maldarelli, F., Strebel,
K., 1996b. The two biological activities of human immunodeficiency virus
type 1 Vpu protein involve two separable structural domains. J. Virol. 70,
809–819.
Schubert, U., Anton, L.C., Bacik, I., Cox, J.H., Bour, S., Bennink, J.R.,
Orlowski, M., Strebel, K., Yewdell, J.W., 1998. CD4 glycoprotein
degradation induced by human immunodeficiency virus type 1 Vpu protein
requires the function of proteasomes and the ubiquitin-conjugating
pathway. J. Virol. 72, 2280–2288.
Sharkey, M.E., Stevenson, M., 2001. Two long terminal repeat circles and
persistent HIV-1 replication. Curr. Opin. Infect. Dis. 14, 5–11.
Sharkey, M.E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan,
J.L., Bucy, R.P., Kostrikis, L.G., Haase, A., Veryard, C., Davaro, R.E.,
Cheeseman, S.H., Daly, J.S., Bova, C., Ellison III, R.T., Mady, B., Lai,
K.K., Moyle, G., Nelson, M., Gazzard, B., Shaunak, S., Stevenson, M.,
2000. Persistence of episomal HIV-1 infection intermediates in patients on
highly active anti-retroviral therapy. Nat. Med. 6, 76–81.
Singh, D.K., Griffin, D.M., Pacyniak, E., Jackson, M., Werle, M.J., Wisdom,
B., Sun, F., Hout, D.R., Pinson, D.M., Gunderson, R.S., Powers, M.F.,
Wong, S.W., Stephens, E.B., 2003. The presence of the casein kinase II
phosphorylation sites of Vpu enhances the CD4+ T cell loss caused by the
simian–human immunodeficiency virus SHIVKU-lbMC33 in pig-tailed
macaques. Virology 313, 435–451.Stephens, E.B., McClure, H.M., Narayan, O., 1995. The proteins of
lymphocyte- and macrophage-tropic strains of simian immunodeficiency
virus are processed differently in macrophages. Virology 206, 535–544.
Stephens, E.B., Mukherjee, S., Sahni, M., Zhuge, W., Raghavan, R., Singh,
D.K., Leung, K., Atkinson, B., Li, Z., Joag, S.V., Liu, Z.Q., Narayan, O.,
1997. A cell-free stock of simian–human immunodeficiency virus that
causes AIDS in pig-tailed macaques has a limited number of amino acid
substitutions in both SIVmac and HIV-1 regions of the genome and has
offered cytotropism. Virology 231, 313–321.
Stephens, E.B., Sahni, M., Leung, K., Raghavan, R., Joag, S.V., Narayan, O.,
1998. Nucleotide substitutions in the long terminal repeat are not required
for development of neurovirulence by simian immunodeficiency virus
strain mac. J. Gen. Virol. 79, 1089–1100.
Stephens, E.B., McCormick, C., Pacyniak, E., Griffin, D., Pinson, D.M., Sun,
F., Nothnick, W., Wong, S.W., Gunderson, R., Berman, N.E., Singh, D.K.,
2002. Deletion of the vpu sequences prior to the env in a simian–human
immunodeficiency virus results in enhanced Env precursor synthesis but is
less pathogenic for pig-tailed macaques. Virology 293, 252–261.
Strebel, K., Klimkait, T., Martin, M.A., 1988. A novel gene of HIV-1, vpu, and
its 16-kilodalton product. Science 241, 1221–1223.
Takeuchi, H., Okada, A., Miura, T., 2003. Roles of the histidine and tryptophan
side chains in the M2 proton channel from influenza A virus. FEBS Lett.
552, 35–38.
Tang, Y., Zaitseva, F., Lamb, R.A., Pinto, L.H., 2002. The gate of the influenza
virus M2 proton channel is formed by a single tryptophan residue. J. Biol.
Chem. 277, 39880–39886.
Teo, I., Veryard, C., Barnes, H., An, S.F., Jones, M., Lantos, P.L., Luthert, P.,
Shaunak, S., 1997. Circular forms of unintegrated human immunodefi-
ciency virus type 1 DNA and high levels of viral protein expression:
association with dementia and multinucleated giant cells in the brains of
patients with AIDS. J. Virol. 71, 2928–2933.
Tiganos, E., Friborg, J., Allain, B., Daniel, N.G., Yao, X.J., Cohen, E.A.,
1998. Structural and functional analysis of the membrane-spanning
domain of the human immunodeficiency virus type 1 Vpu protein.
Virology 251, 96–107.
Wang, C., Lamb, R.A., Pinto, L.H., 1995. Activation of the M2 ion channel of
influenza virus: a role for the transmembrane domain histidine residue.
Biophys. J. 69, 1363–1371.
Wray, V., Kinder, R., Federau, T., Henklein, P., Bechinger, B., Schubert, U.,
1999. Solution structure and orientation of the transmembrane anchor
domain of the HIV-1-encoded virus protein U by high-resolution and solid-
state NMR spectroscopy. Biochemistry 38, 5272–5282.
Yao, X.J., Garzon, S., Boisvert, F., Haseltine, W.A., Cohen, E.A., 1993. The
effect of vpu on HIV-1-induced syncytia formation. J. Acquired Immune
Defic. Syndr. 6, 135–141.
Zazzi, M., Romano, L., Catucci, M., Venturi, G., De Milito, A., Almi, P.,
Gonnelli, A., Rubino, M., Occhini, U., Valensin, P.E., 1997. Evaluation of
the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular
predictor of disease progression. J. Med. Virol. 52, 20–25.
